Which medical specialty do you think is most vulnerable to Artificial intelligence?

Who will be eliminated first?

(Note: Of course, every department is valuable, only these branches were written in line with the data)

🚨🔥ASCO #ASCO24 OncoAlert

Inviting #LCSM colleagues to:

✅A Case-Based #EducationSession , I’m honored to chair, joined by great experts/colleagues:Jonathan Spicer MD PhD Henry S. Park, MD, MPH Anne-Marie Dingemans on:

Locally Advanced Non-Small Cell #LungCancer

⏰Sun, June 2 at 11:30
📍Hall D1

Thank you Yakup Ergün for highlighting the results of our work that will be presented at ASCO soon.

Intriguing findings on prognosis of young patients harboring BRCA PV, thanks to a tremendous international effort lead by Matteo Lambertini, MD PhD!

June 3rd - Stay tuned OncoAlert

Looking forward to presenting this analysis conducted in collaboration with Yale University, where we look at outcomes with T-DXd in 1500 pts with MBC, analyzed by HER2 status (positive, low, 0), HR status, line of treatment and prior SG. Thanks for the shoutout Yakup Ergün! #ASCO24

#ASCO24
Real-world data from the largest dataset to date on the efficacy of T-DXd in mBC.

Of course, it will be presented by the master of HER-Low and ADCs, Paolo Tarantino💥

📌You should definitely take a look at this study. There is very valuable data on the HR situation and

#ASCO24
Luminal-type BC is known to have the best prognosis among subtypes. However, is the situation different for those with BRCA mutations?

The study by Luca Arecco, MD and colleagues presents very interesting results.
This presentation is not to be missed.

Oral abstract #504

TOP 10 abstract list regarding kidney and bladder cancer by the OncoAlert GU team for #ASCO24 👇

Emre Yekedüz Dra. María Natalia Gandur Quiroga Gil Morgan, MD 🌐

Tattoos as a risk factor for malignant lymphoma: a population-based case–control study

💥According to this epidemiological study, tattoo exposure is associated with an increased risk of lymphoma‼️ (Especially DLBCL and follicular lymphoma)

OncoAlert
thelancet.com/journals/eclin…

#ASCO24

T-DXd vs T-DM in patients with HER2+ mBC: Updated survival results of DESTINY-Breast03

PFS➡️29.0 vs 7.2 mo
OS➡️52.6 vs 42.7 mo
ORR➡️79% vs 37%

ILD➡️16.7% vs 3.4% (all <G4)

meetings.asco.org/abstracts-pres…

Less than a week to what promises to be a terrific ASCO24. Multiple trials with practice changing potential, including with ADCs challenging our HER2 categories, CDK4/6 inhibitors beyond progression, adjuvant IO for TNBC and much more. See you in Chicago next week! #bcsm #ASCO24

#ASCO24

DESTINY-Breast07: T-DXd and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC (phase 1b/2)

Confirmed ORR
T-DXD➡️77.3%
T-DXd +P➡️82%

1y PFS➡️77.3% and 89.4%

>G3 AE➡️ 50.7% and 54%
ILD➡️8% and 10% (all <G3)

OncoAlert
meetings.asco.org/abstracts-pres…

Some of the highlights while waiting for #ASCO24

Ab#1005
Enfortumab vedotin in TNBC and HR+/HER2- breast cancer (BC) cohorts of EV-202.

🔍64% of pts with TNBC received ≥2L systemic tx, 73% of HR+ pts received ≥3L

ORR
TNBC➡️%19
HR+➡️15.6%

OncoAlert
meetings.asco.org/abstracts-pres…

The policy of some journals (especially those in the LANCET group) to collect accepted letters under a single heading is quite unfair. Clinical trial articles are usually written by writing teams supported by industry sponsors and often bring together many researchers. In

Dear Colleagues,
The OncoAlert 🚨Network Presents OUR Picks of
TOP 🔟Abstracts to be Presented at #ASCO24

This List Curated by:
#OncoAlertAF Leads : Elisa Agostinetto 🇧🇪 Elisabetta Bonzano 🇮🇹 Gil Morgan, MD 🇺🇸
With our distinguished OncoAlert Faculty:
Erika Hamilton, MD 🇺🇸 Stephanie Graff, MD, FACP, FASCO

Dear #ASCO24
We Are Here‼️
We Are OncoAlert 🚨

Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature

💥An excellent review on the gonoadotoxicity of new anticancer agents👇

OncoAlert
cancertreatmentreviews.com/article/S0305-…

🔥🚨Hot off the press.

ASCO launched a NEW meetings #Mobile APP.

Such a great, user-friendly APP that makes navigating #ASCO24 meeting, and accessing agenda & all resources, much easier.

For Apple users 👇🏼
apps.apple.com/app/id64737207…

For Android users 👇🏼
play.google.com/store/apps/det…

Dear Colleagues,
ONE WEEK until #ASCO24 🌐
WE ARE READY
WE ARE OncoAlert 🚨

#OncoAlertAF
Dra. María Natalia Gandur Quiroga 🇦🇷
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz 🇺🇸
Hidehito HORINOUCHI 🇯🇵
Fadi Haddad, MD 🇺🇸
Dr. Iván R. González 🇲🇽

Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes

💥An excellent review👇

OncoAlert
cancertreatmentreviews.com/article/S0305-…

Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC

🔍47.7% patients had investigator-assessed visceral crisis

R+ET vs ChT
mPFS➡️21.8 vs 12.8 mo
ORR➡️66.1% vs 61.8%

OncoAlert
ascopubs.org/doi/10.1200/JC…